Summer Sale
50% off Premium Yearly
Opinions Michael Smedley
Knight TherapeuticsGUD.TOCOMMENTAug 15, 2017
Michael SmedleyStock price when the opinion was issued
As of Jun 19, 2026. Market Open.
You might be interested:
Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research. Trades at a cheap valuation. Investors’ patience has run out. Recent acquisition gave it a new life. Current environment can be favorable. Unlock Premium - Try 5i Free
Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. Although the stock has not moved, the basic thesis has not changed. There is some weakness in South America which has impacted their acquisition. With no dividend, there is an opportunity cost to the stock, but outlook remains intact. Unlock Premium - Try 5i Free
Stockchase Insights
James Hodgins
Ryan ModestoHis biggest holding. They have $6.85 in tangible book value, mostly cash. The CEO may buy Paladin or Cipher Pharmaceuticals. Be patient for this deal. It'll be accretive.
James Hodgins
There is tremendous competence on the part of Jonathan Goodman. You have to be patient with this to get the same return that you got from his previous Paladin Labs company. He is very good with his skills, connections and financing ability for future products that come his way. Unusual investments in funds that are in the pipes of products he is interested in.